Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 87.01 USD 0.07% Market Closed
Market Cap: 4.2B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Axsome Therapeutics Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Axsome Therapeutics Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Axsome Therapeutics Inc
NASDAQ:AXSM
Accounts Receivables
$124.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Receivables
$16.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Receivables
$9.7B
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
18%
Pfizer Inc
NYSE:PFE
Accounts Receivables
$11.4B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Accounts Receivables
$11.4B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Accounts Receivables
$10.3B
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
11%
No Stocks Found

Axsome Therapeutics Inc
Glance View

Market Cap
4.2B USD
Industry
Pharmaceuticals

Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.

AXSM Intrinsic Value
94.15 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Axsome Therapeutics Inc's Accounts Receivables?
Accounts Receivables
124.1m USD

Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Accounts Receivables amounts to 124.1m USD.

What is Axsome Therapeutics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
58%

Over the last year, the Accounts Receivables growth was 58%.

Back to Top